Heart failure & cardiomyopathiesTrial design
Rivaroxaban for Stroke Prevention in Hypertrophic Cardiomyopathy Without Atrial Fibrillation and With Impaired Left Atrial Reservoir Strain: Design and Rationale of the LA-HCM Randomized Trial
- prospective, multicentre, randomized, open-label trial with blinded endpoint adjudication (PROBE design)
- sponsored by Rennes University Hospital
- conducted in 17 French centres
- design and rationale
Study context
- Population
- Adults with hypertrophic cardiomyopathy (HCM), sinus rhythm, no documented atrial fibrillation (AF), and core-laboratory-confirmed left atrial reservoir strain (LARS) ≤20%planned enrolment, followed for 24 months
- Participants
- 532 adults
- Planned comparison
- rivaroxaban or standard care
- Primary endpoint
- Composite of all-cause death, myocardial infarction, ischemic stroke-including newly detected silent cerebral infarction on paired baseline and 24-month brain MRI-and systemic embolism
- Follow-up
- 24 months
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Rivaroxaban for Stroke Prevention in Hypertrophic Cardiomyopathy Without Atrial Fibrillation and With Impaired Left Atrial Reservoir Strain: Design and Rationale of the LA-HCM Randomized Trial. Eur Heart J Cardiovasc Imaging. Published 8 October 2026. doi:10.1093/ehjci/jeag280
Summarised from the published abstract; every number is checked against it